The packet lists no genes, inheritance pattern, or molecular mechanism, so the cause is not described here. The definition states only that the tumor is presumably derived from Rathke pouch epithelium.

The packet supplies no diagnostic criteria or testing information. The definition describes two clinicopathological forms, adamantinomatous and papillary craniopharyngioma.

The packet contains no FDA-approved treatment records, orphan drug designations, or foundational therapy content for this condition, so established treatment is not described here.

According to the disease definition, adapted from WHO, the most significant factor associated with recurrence is the extent of surgical resection, and lesions greater than 5 cm in diameter carry a markedly worse prognosis. Further natural-history or outcome information is not certified in this packet.

ClinicalTrials.gov records in the packet include studies with varied statuses. St. Jude Children's Research Hospital is listed as sponsor of two phase 2 trials with titles referring to proton therapy for craniopharyngioma (NCT02792582 and NCT01419067), both active and not recruiting. University Hospital, Angers is listed as sponsor of a phase 3 trial (NCT07845994, not yet recruiting, estimated start 2026-11-01) titled as a study of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17. Maastricht Radiation Oncology is listed as sponsor of a neuro-oncology proton therapy research infrastructure study (NCT04648462, recruiting). Trial titles describe study focus and do not establish outcomes. The packet's publication digest is dominated by reviews and meta-analyses.